Ушбу иш иқтибос қилган ишлар

89 та иш

Иш: Modelling of the Innate and Adaptive Immune Response to SARS Viral Infection, Cytokine Storm and Vaccination

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

   Chaolin Huang, Yeming Wang, Xingwang Li +26

   Мақола202021 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.071145

2. The trinity of COVID-19: immunity, inflammation and intervention

   Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia +2

   Шарҳ мақола20204 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204770

3. Overview of the immune response

   David Chaplin

   Шарҳ мақола20103 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204744

4. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

   Jérôme Hadjadj, Nader Yatim, Laura Barnabei +27

   Мақола20203 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204775

5. Mathematical model of antiviral immune response. I. Data analysis, generalized picture construction and parameters evaluation for hepatitis B

   G. I. Marchuk, Petrov Rv, A. A. Romanyukha +1

   Мақола19912 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204720

6. Viruses and interferon: a fight for supremacy

   Michael G. Katze, Yupeng He, Michael Gale

   Шарҳ мақола20022 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204740

7. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

   Rudragouda Channappanavar, Stanley Perlman

   Шарҳ мақола20172 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204764

8. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper

   Sonu Bhaskar, Akansha Sinha, Maciej Banach +6

   Мақола20202 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204774

9. SARS-CoV-2 viral load is associated with increased disease severity and mortality

   Jesse Fajnzylber, James Regan, Kendyll Coxen +97

   Мақола20202 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204779

10. Risk factors for severe and critically ill COVID‐19 patients: A review

    Yadong Gao, Mei Ding, Xiang Dong +17

    Шарҳ мақола20202 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204780

11. The ‘cytokine storm’: molecular mechanisms and therapeutic prospects

    Rajendra Karki, Thirumala‐Devi Kanneganti

    Шарҳ мақола20212 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204785

12. Innate immunity: the first line of defense against SARS-CoV-2

    Michael Diamond, Thirumala‐Devi Kanneganti

    Шарҳ мақола20222 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204793

13. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204713

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204714

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204715

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204716

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204717

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204718

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204719

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204721

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204722

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204723

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204724

24. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204725

25. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204726